- Home
- MBRX vs PRTG Comparison
MBRX vs PRTG Comparison
Compare MBRX & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- PRTG
- Stock Information
- Founded
- MBRX 2015
- PRTG 1973
- Country
- MBRX United States
- PRTG British Virgin Islands
- Employees
- MBRX N/A
- PRTG N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- PRTG Oil & Gas Production
- Sector
- MBRX Health Care
- PRTG Energy
- Exchange
- MBRX Nasdaq
- PRTG Nasdaq
- Market Cap
- MBRX 5.7M
- PRTG 4.7M
- IPO Year
- MBRX 2016
- PRTG N/A
- Fundamental
- Price
- MBRX $1.88
- PRTG $4.10
- Analyst Decision
- MBRX Strong Buy
- PRTG
- Analyst Count
- MBRX 2
- PRTG 0
- Target Price
- MBRX $24.00
- PRTG N/A
- AVG Volume (30 Days)
- MBRX 62.3K
- PRTG 128.0K
- Earning Date
- MBRX 11-08-2024
- PRTG 02-26-2025
- Dividend Yield
- MBRX N/A
- PRTG N/A
- EPS Growth
- MBRX N/A
- PRTG N/A
- EPS
- MBRX N/A
- PRTG N/A
- Revenue
- MBRX N/A
- PRTG N/A
- Revenue This Year
- MBRX N/A
- PRTG N/A
- Revenue Next Year
- MBRX N/A
- PRTG N/A
- P/E Ratio
- MBRX N/A
- PRTG N/A
- Revenue Growth
- MBRX N/A
- PRTG N/A
- 52 Week Low
- MBRX $0.40
- PRTG $2.10
- 52 Week High
- MBRX $6.24
- PRTG $25.16
- Technical
- Relative Strength Index (RSI)
- MBRX 47.84
- PRTG 42.95
- Support Level
- MBRX $1.65
- PRTG $3.86
- Resistance Level
- MBRX $1.99
- PRTG $4.98
- Average True Range (ATR)
- MBRX 0.20
- PRTG 0.54
- MACD
- MBRX 0.04
- PRTG -0.15
- Stochastic Oscillator
- MBRX 71.79
- PRTG 11.53
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.